Literature DB >> 27573851

Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research.

Jun-Xu Li1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27573851      PMCID： PMC5027450          DOI： 10.1073/pnas.1612752113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  15 in total

Review 1.  Principles of drug abuse liability assessment in laboratory animals.

Authors:  Nancy A Ator; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2003-06-05       Impact factor: 4.492

2.  Cloning of a delta opioid receptor by functional expression.

Authors:  C J Evans; D E Keith; H Morrison; K Magendzo; R H Edwards
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

3.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

4.  A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.

Authors:  Eugene R Viscusi; Lynn Webster; Michael Kuss; Stephen Daniels; James A Bolognese; Seth Zuckerman; David G Soergel; Ruth Ann Subach; Emily Cook; Franck Skobieranda
Journal:  Pain       Date:  2016-01       Impact factor: 6.961

Review 5.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

6.  A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Authors:  Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Molecular cloning and functional expression of a mu-opioid receptor from rat brain.

Authors:  Y Chen; A Mestek; J Liu; J A Hurley; L Yu
Journal:  Mol Pharmacol       Date:  1993-07       Impact factor: 4.436

9.  Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.

Authors:  Claire L Neilan; Stephen M Husbands; Simon Breeden; M C Holden Ko; Mario D Aceto; John W Lewis; James H Woods; John R Traynor
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

Review 10.  Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Authors:  Jennifer S Orman; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more
  2 in total

Review 1.  Designing Safer Analgesics via μ-Opioid Receptor Pathways.

Authors:  H C Stephen Chan; Dillon McCarthy; Jianing Li; Krzysztof Palczewski; Shuguang Yuan
Journal:  Trends Pharmacol Sci       Date:  2017-09-19       Impact factor: 14.819

Review 2.  Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.

Authors:  Flaminia Coluzzi; Laura Rullo; Maria Sole Scerpa; Loredana Maria Losapio; Monica Rocco; Domenico Billeci; Sanzio Candeletti; Patrizia Romualdi
Journal:  CNS Drugs       Date:  2022-05-26       Impact factor: 6.497
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.